Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical And Radiological Response Among Patients With Multiple Sclerosis Who Switched From Natalizumab To Fingolimod: Experience from a centre in Spain

Next Previous
Trial Profile

Clinical And Radiological Response Among Patients With Multiple Sclerosis Who Switched From Natalizumab To Fingolimod: Experience from a centre in Spain

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Jun 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fingolimod (Primary) ; Natalizumab
  • Indications Multiple sclerosis
  • Focus Therapeutic Use

Most Recent Events

  • 09 Jun 2015 New trial record
  • 25 Apr 2015 Results (Risk of Rebound) presented at the 67th Annual Meeting of the American Academy of Neurology.
  • 25 Apr 2015 Results (Clinical And Radiological Response) presented at the 67th Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top